Latest Artrya (ASX:AYA) News

Artrya Limited has secured A$15 million through a two-tranche placement aimed at accelerating regulatory approvals and commercial rollout of its Salix® coronary artery disease diagnostic software in the US.

Artrya has secured a pivotal three-year commercial contract with Sonic Healthcare Australia to deploy its AI-driven Salix Coronary Anatomy platform across over 125 radiology centres, marking a significant step in commercialising its coronary artery disease diagnostic technology.

Artrya Limited reports solid progress on its FDA 510(k) application and secures a A$5 million capital raise, positioning itself for imminent commercial rollout in the US healthcare sector.

Artrya Limited has responded to an ASX price query following a notable surge in its share price, confirming no undisclosed information and adherence to continuous disclosure rules.